RALES Trial
New England Journal of Medicine (1999)
25mg daily reduced all-cause mortality by 30% in 1,663 severe HFrEF patients.
Spironolactone
Oral tablet (100mg)Available in all 50 statesMarketing purposes only. Actual medications, if prescribed, are dispensed by a licensed pharmacy.
heart
Aldosterone antagonist and anti-androgenic agent. Cornerstone in heart failure (RALES: 30% mortality reduction), resistant hypertension, and women's health (acne, hirsutism, female-pattern hair loss).
30% mortality reduction in HFrEF (RALES)
Potassium-sparing
Anti-fibrotic cardiac/renal effects
Anti-androgenic benefits for PCOS, acne, hirsutism
No commitment · HSA/FSA eligibleNo commitment · HSA/FSA eligible
How it works
Competitively inhibits aldosterone at mineralocorticoid receptors, reducing sodium reabsorption and potassium loss. Also binds androgen receptors (anti-androgenic). MR blockade reduces fibrosis, inflammation, and oxidative stress beyond the kidney.
Every Marek client receives this baseline panel before a provider review. Your provider may add additional biomarkers based on your health history, symptoms, and goals, pulling from 1,000+ available markers. See more biomarkers →
Sex hormones
Adrenals & neurosteroids
Growth hormone / IGF-1
Thyroid hormones
Cardiovascular health
Insulin sensitivity
Liver & pancreas
Kidney function
Comprehensive Metabolic Panel (CMP)
Prostate health
Vitamins & minerals
Iron status
Complete Blood Count (CBC)
Clinical evidence
New England Journal of Medicine (1999)
25mg daily reduced all-cause mortality by 30% in 1,663 severe HFrEF patients.
Safety profile
FAQ
Aldosterone antagonist and anti-androgenic agent. Cornerstone in heart failure (RALES: 30% mortality reduction), resistant hypertension, and women's health (acne, hirsutism, female-pattern hair loss).
Treatments are dependent on licensed clinical prescription. Client costs vary based on individual labs and panel in treatments and services.